Preclinical toxicological assessment of levothyroxine and liothyronine Maillard impurities

BACKGROUND: Following the introduction of new stability-indicating related substances methods, an unknown impurity was observed in levothyroxine (LeMI) and liothyronine (LiMI) tablets (ADVANZ PHARMA) in concentrations ≥1.0%, from 6 months of storage onwards. The impurity was identified as a Maillard...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Anju, Asif, Muhammad, Deshmukh, Rajeev, Vinchurkar, Mohini, Singana, Suresh B, Bhondave, Pratik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618099/
https://www.ncbi.nlm.nih.gov/pubmed/36330073
http://dx.doi.org/10.1093/toxres/tfac047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618099/
https://www.ncbi.nlm.nih.gov/pubmed/36330073
http://dx.doi.org/10.1093/toxres/tfac047

Ejemplares similares